Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Core Insights - Olema Pharmaceuticals is set to present a trial-in-progress poster for the Phase 3 OPERA-02 trial at the 2025 San Antonio Breast Cancer Symposium, focusing on the combination of palazestrant and ribociclib for treating advanced ER+/HER2- breast cancer [1][2] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving treatment standards and outcomes for breast cancer patients, with a focus on developing targeted therapies [3] - The company is advancing a pipeline that includes palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3][4] Product Details - Palazestrant (OP-1250) is being investigated for its efficacy in recurrent, locally advanced, or metastatic ER+/HER2- breast cancer, demonstrating complete blockage of ER-driven transcriptional activity and anti-tumor efficacy [4] - The product has received FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after endocrine therapy, with ongoing evaluations in pivotal Phase 3 trials OPERA-01 and OPERA-02 [4]